Clinical trials: Immune Checkpoint Blockade
Resectable Hepatocellular Carcinoma
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma.
- Trial name
- NCT05578430
- Testing
- Cadonilimab, TACE, Surgery
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Metastatic Melanoma
SBRT as a Vaccination for Metastatic Melanoma
Immunotherapy with PD-1 blockade is a first-line treatment for patients with advanced melanoma, but unfortunately most patients progress on this therapy.
- Trial name
- NCT04042506
- Testing
- Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Muscle-invasive Urothelial Cancer of the Bladder
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical…
- Trial name
- NCT02621151
- Testing
- Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to…
- Trial name
- CheckPAC (NCT02866383)
- Testing
- Nivolumab, Ipilimumab, Radiotherapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Herlev Hospital
Cutaneous Metastases
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in…
- Trial name
- NCT05481658
- Testing
- Diphencyprone (DPCP)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nicholas Gulati
ICB-refractory Melanoma
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with ICI-refractory melanoma who are receiving the combination of ipilimumab and nivolumab as part of…
- Trial name
- NCT06250335
- Testing
- Prebiotic Food-Enriched Diet, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer, Cancer of the Endometrium
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Patients with inoperable endometrial cancer have limited treatment options. PD-L1 expression is common in endometrial cancers and RT induces tumor and systemic changes that induce the immune system.
- Trial name
- NCT03955978
- Testing
- TSR-042, Brachytherapy, Endometrial biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Solid Tumor, Adult
Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer…
- Trial name
- ICONIC (NCT07487805)
- Testing
- Intermediate-dose ivermectin, High-dose ivermectin
- Volunteers
- 80 people
- Sponsor
- University of Florida
Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma
- Trial name
- NCT03396952
- Testing
- Aspirin, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Neoplasms, Endometrial
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or…
- Trial name
- NCT07684599
- Testing
- Mocertatug rezetecan, Dostarlimab, Pembrolizumab
- Where
- 8 sites in Japan
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Lung Diseases, Interstitial, NSCLC
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade exposure, and correlate the…
- Conditions
- Lung Diseases, Interstitial, NSCLC, Immunotherapy
- Trial name
- NCT04807114
- Testing
- Immune checkpoint inhibitor, Chemotherapy + Immune checkpoint inhibitor
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Thymic Epithelial Tumor, Recurrent Thymoma
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Background: Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT04417660
- Testing
- M7824
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Metastatic Cancer
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
This phase 1 clinical trial aims to evaluate the safety, tolerability and feasibility of combination treatment of High Intensity Focused Ultrasound Histotripsy (HIFU-HT) and immune checkpoint inhibitors (ICI) in adult patients…
- Trial name
- iFOCUS (NCT06524570)
- Testing
- HIFU-HT, ICI
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- UMC Utrecht
Cancer
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
- Trial name
- NCT06754501
- Testing
- Atezolizumab, Tiragolumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer.
- Trial name
- BreastVAX (NCT04454528)
- Testing
- Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pseudomyxoma Peritonei
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years.
- Trial name
- Pseudovax (NCT07341360)
- Testing
- Pseudovax, Molgramostim, Tislelizumab
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Acute Myeloid Leukemia
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
The clinical trial will test the safety and tolerability of a combination therapy (azacitidine in combination with two checkpoint inhibitors, nivolumab [Anti-PD1] and relatlimab [Anti-LAG3]) in patients with relapsed/refractory…
- Trial name
- AARON (NCT04913922)
- Testing
- Azacitidine Injection, Nivolumab, Relatlimab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pancreas Cancer
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.
- Trial name
- CHECKPOINT (NCT05435053)
- Testing
- Nivolumab, Irreversible electroporation (IRE)
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Ismail Gögenur